Researchers aimed to determine whether iron metabolism and serum hepcidin levels were linked to osteoporosis in patients with rheumatoid arthritis.
Abaloparatide treatment significantly increases bone mineral density in younger postmenopausal women at high risk for fracture.
Researchers assessed the association between serum uric acid levels and osteoporosis risk in postmenopausal women with rheumatoid arthritis.
Inhibition of sclerostin with romosozumab may increase cardiovascular risk.
Researchers evaluated the effects of follow-up therapy after denosumab discontinuation on bone resorption, bone mineral density, and clinical fracture risk.
Elderly patients with hip fracture have an increased risk for suicide.
The FDA has approved Crysvita for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.
Researchers assessed the impact of primary hand osteoarthritis on bone mass, microstructure, and biomechanics in the affected skeletal regions.
Researchers examined the association between fractures and Parkinson disease during the prodromal period.
Individuals with diabetes have an increased risk for hip and nonvertebral fractures.